Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

The current study -- HERIZON-GEA-01 -- was designed before the data from KEYNOTE-811 was revealed. That trial showed that ...

Datopotamab deruxtecan received FDA approval for HR+/HER2– breast cancer, improving progression-free survival and overall response rate compared to chemotherapy. Trastuzumab deruxtecan plus pertuzumab ...

In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...

Impact of body mass index (BMI) on survival outcomes in patients with cancer treated with immune checkpoint inhibitors (ICPI): A systematic review and meta analysis. This is an ASCO Meeting Abstract ...

Adding Keytruda to chemotherapy improved survival outcomes in patients with endometrial cancer, regardless of their mismatch repair or PD-L1 status. Keytruda (pembrolizumab) plus chemotherapy improved ...

Givastomig, a CLDN18.2 x 4-1BB bispecific antibody, continues to show robust efficacy when combined with nivolumab and ...